Brief: Lupin Receives Tentative U.S. FDA Approval For Apixaban Oral Suspension 1.25Mg/Ml Via 505(B)(2)
28/09/2026 05:38
BRIEF-Lupin Receives Tentative U.S. FDA Approval For Apixaban Oral Suspension 1.25Mg/Ml Via 505(B)(2) Sept 28 (Reuters) - Lupin Limited LUPN.NS:
RECEIVES TENTATIVE FDA APPROVAL FOR APIXABAN ORAL SUSPENSION 1.25MG/ML VIA 505(B)(2)
TO MANUFACTURE APIXABAN ORAL SUSPENSION AT SOMERSET, NEW JERSEY FACILITY UPON FINAL APPROVAL
Further company coverage: LUPN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lupin
See all newsIndia's Lupin gains after US FDA nod for Phytonadione Injectable Emulsion
Brief: Lupin Receives U.S. FDA Approval For Phytonadione Injectable Emulsion
Brief: Lupin Announces Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines
Brief: Lupin Receives Tentative U.S. FDA Approval For Apixaban Oral Suspension 1.25Mg/Ml Via 505(B)(2)
Lupin may pursue deals worth up to $2 billion, Nomura says